Literature DB >> 8745846

Evaluation of the suitability of weekly peak expiratory flow rate measurements in monitoring annual decline in lung function among patients with asthma and chronic bronchitis.

P R Tirimanna1, J J Den Otter, C P Van Schayck, C L Van Herwaarden, H Folgering, C Van Weel.   

Abstract

BACKGROUND: Early detection and treatment of patients with asthma or chronic bronchitis who have a rapid annual decline in lung function is essential in order to improve their long-term prognosis. This annual rate of decline can be assessed accurately by monitoring the forced expiratory volume in one second (FEV1) which is a routine procedure in hospital respiratory laboratories but not in general practice. General practitioners usually measure patients' peak expiratory flow rate (peak flow) to evaluate lung function. If annual decline in lung function can be assessed by monitoring peak flow, this method could be used in general practice for detecting patients at an early stage who have a rapid decline. AIM: A study aimed to investigate the long-term correlation between FEV1 and peak flow among a group of patients in Nijmegen, the Netherlands.
METHOD: FEV1 and peak flow were monitored in 53 patients with moderate asthma and 78 patients with moderate chronic bronchitis over four years. FEV1 was measured in a laboratory once every six months and peak flow was measured by patients once a week. The correlation between the two sets of measurements was studied for each patient.
RESULTS: Four-year data for 83 of the 131 patients were analysed; the other 48 patients received inhaled steroids during the second half of the study period so their data were not considered for all the analyses. Of the 83 patients, 35 (42%) showed a decrease in both FEV1 and peak flow. Thirty six patients (43%) showed a decrease in FEV1 and an increase in peak flow. Four patients (5%) showed an increase in FEV1 and a decrease in peak flow and eight patients (10%) showed an increase in both rates. Approximately similar results were seen in a separate analysis of all 131 patients during the first two years of the study.
CONCLUSION: No long-term correlation was found between FEV1 and peak flow. Peak flow is not capable of detecting annual decline in lung function. Therefore it cannot be used to detect patients with asthma or chronic bronchitis who have a rapid annual decline in lung function. Spirometers, which measure peak flow and FEV1, could be used in general practice. These would allow general practitioners to continue measuring peak flow in order to assess short-term changes in lung function while providing an important means for monitoring FEV1 to assess long-term changes in lung function.

Entities:  

Mesh:

Year:  1996        PMID: 8745846      PMCID: PMC1239505     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  12 in total

Review 1.  The use of peak expiratory flow rate measurements in respiratory disease.

Authors:  M D Lebowitz
Journal:  Pediatr Pulmonol       Date:  1991

2.  Accuracy, precision and linearity of the portable flow-volume meter Microspiro HI-298.

Authors:  E Dompeling; C P van Schayck; H Folgering; H J van den Hoogen; C van Weel
Journal:  Eur Respir J       Date:  1991-05       Impact factor: 16.671

3.  Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction.

Authors:  C A Kelly; G J Gibson
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

4.  Rate of decline of lung function in subjects with asthma.

Authors:  J K Peat; A J Woolcock; K Cullen
Journal:  Eur J Respir Dis       Date:  1987-03

5.  A descriptive analysis of the growth and decline of the FVC and FEV1.

Authors:  B Burrows; M G Cline; R J Knudson; L M Taussig; M D Lebowitz
Journal:  Chest       Date:  1983-05       Impact factor: 9.410

6.  Accuracy and reproducibility of the Assess peak flow meter.

Authors:  C P van Schayck; E Dompeling; C van Weel; H Folgering; H J van den Hoogen
Journal:  Eur Respir J       Date:  1990-03       Impact factor: 16.671

7.  Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study.

Authors:  E Dompeling; C P van Schayck; P M van Grunsven; C L van Herwaarden; R Akkermans; J Molema; H Folgering; C van Weel
Journal:  Ann Intern Med       Date:  1993-05-15       Impact factor: 25.391

8.  Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction.

Authors:  F W Dekker; A C Schrier; P J Sterk; J H Dijkman
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

9.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.

Authors:  G Boman; U Bäcker; S Larsson; B Melander; L Wåhlander
Journal:  Eur J Respir Dis       Date:  1983-08

10.  Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.

Authors:  C P van Schayck; E Dompeling; C L van Herwaarden; H Folgering; A L Verbeek; H J van der Hoogen; C van Weel
Journal:  BMJ       Date:  1991-12-07
View more
  3 in total

1.  Factors Contributing to 50-ft Walking Speed and Observed Ethnic Differences in Older Community-Dwelling Mexican Americans and European Americans.

Authors:  Myla U Quiben; Helen P Hazuda
Journal:  Phys Ther       Date:  2015-01-15

2.  Development of a novel tool for engaging children and parents in asthma self-management.

Authors:  Flory L Nkoy; Bryan L Stone; Bernhard A Fassl; Karmella Koopmeiners; Sarah Halbern; Eun H Kim; Justin Poll; Joseph W Hales; Dillon Lee; Christopher G Maloney
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

3.  Diagnosis of asthma and chronic obstructive pulmonary disease in general practice.

Authors:  C P Van Schayck
Journal:  Br J Gen Pract       Date:  1996-03       Impact factor: 5.386

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.